These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8915488)

  • 1. Evaluation of new putative tumor markers for melanoma.
    Miliotes G; Lyman GH; Cruse CW; Puleo C; Albertini PA; Rapaport D; Glass F; Fenske N; Soriano T; Cuny C; Van Voorhis N; Reintgen D
    Ann Surg Oncol; 1996 Nov; 3(6):558-63. PubMed ID: 8915488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of putative tumor markers for malignant melanoma.
    Reintgen DS; Cruse CW; Wells KE; Saba HI; Fabri PJ
    Ann Plast Surg; 1992 Jan; 28(1):55-9. PubMed ID: 1642407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum markers for melanoma].
    Ugurel S
    Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
    Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
    Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.
    Smit LH; Nieweg OE; Korse CM; Bonfrer JM; Kroon BB
    J Surg Oncol; 2005 May; 90(2):66-9; discussion 69-70. PubMed ID: 15844182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent malignant melanoma: the identification of prognostic factors to predict survival.
    Reintgen DS; Cox C; Slingluff CL; Seigler HF
    Ann Plast Surg; 1992 Jan; 28(1):45-9. PubMed ID: 1642405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
    Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
    Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma.
    Curry BJ; Farrelly M; Hersey P
    Melanoma Res; 1999 Dec; 9(6):557-67. PubMed ID: 10661766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
    Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
    Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma.
    Kelley MC; Jones RC; Gupta RK; Yee R; Stern S; Wanek L; Morton DL
    Cancer; 1998 Oct; 83(7):1355-61. PubMed ID: 9762936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
    Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
    Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.
    Spanknebel K; Coit DG; Bieligk SC; Gonen M; Rosai J; Klimstra DS
    Am J Surg Pathol; 2005 Mar; 29(3):305-17. PubMed ID: 15725798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
    Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
    Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of S100 and survival in metastatic malignant melanoma.
    Buer J; Probst M; Franzke A; Duensing S; Haindl J; Volkenandt M; Wittke F; Hoffmann R; Ganser A; Atzpodien J
    Br J Cancer; 1997; 75(9):1373-6. PubMed ID: 9155061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma.
    Ranieri JM; Wagner JD; Wiebke EA; Azuaje R; Smith ML; Wenck S; Daggy J; Coleman JJ
    Plast Reconstr Surg; 2005 Apr; 115(4):1058-63. PubMed ID: 15793446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.